drugset / Trial / NCT07597902
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).
Timeline
- Start
- 2026-06-01
- Primary completion
- 2028-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 200 mg | Oral |
| Subject | Nirmatrelvir | Small molecule | 150 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 100 mg | Oral |
| Subject | Valacyclovir | Unknown | 1500 mg | Oral |